作者: Halder, Tripti ; Acharya, Niyati ; Kaushik, Vishakha ; Barot, Harshit ; Kumar, Bhavna ; Bhut, Hastik ; Saha, Bijit ; Poddar, Sibani ; Patel, Hiren

:Biodegradable polymers, encompassing both natural and synthetic polymers, have demonstrated efficacy as carriers for synthetic drugs, natural bioactive molecules, and inorganic metals. This is due to their ability to control the release of these substances. As a result, various advanced materials, such as nanoparticle- loaded hydrogels, nanofibrous scaffolds, and nanocomposites, have been developed. These materials have shown promise in enhancing processes, such as cell proliferation, vascular angiogenesis, hair growth, and wound healing management. Natural polymers, including hyaluronic acid, collagen, chitosan, gelatin, and alginate, as well as synthetic polymers like polylactic acid, polyglycolic acid, polylactic co-glycolic acid, and PCA, have significant potential for promoting wound healing. This study examines the advancements in biodegradable polymers for wound healing, specifically focusing on each polymer and its distinctive formulations. It also discusses the in-vitro experiments conducted using different cell lines, as well as the in-vivo studies that explore the numerous uses of these polymers in wound healing. The discussion also included the exploration of modifications or combinations of several polymers, as well as surface changes, in order to produce synergistic effects and address the limitations of individual polymers. The goal was to expedite the healing process of different chronic wounds. Due to this, there have been notable advancements in the technological use of polymeric mixes, including biodegradable polymer-based scaffolds, which have accelerated the process of wound healing.

2024-02-01·Drug Development Research

Development and evaluation of multi‐functionalized sialic acid conjugated asiatic acid nanoconstruct to mitigate cognitive deficits in Alzheimer's disease

Article

作者: Acharya, Sanjeev ; Saha, Bijit ; Halder, Tripti ; Dhas, Namdev ; Acharya, Niyati

AbstractSialic acid (SA) serves a critical role in neuronal repair and cognitive functions. SA is a nine‐carbon carboxylated sugar with a glycoconjugate cap that acts as a ligand and surface decoration with SA facilitates delivery to the target site. The present research aimed to develop SA surface modified AA nanostructured lipid carrier (NLCs) with carbodiimide conjugation method. Sterylamine, poloxamer 188 and tween 80 were used as surfactants and several characterization studies including, differential scanning calorimetry, fourier transform infrared spectroscopy and x‐ray photon spectroscopy were analyzed. Further, in vitro, neuroprotective efficiency was evaluated in SH‐SY5Y cells and hCMEC/D3 cells and found significant potential effects with the treatments of developed NLCs. Pharmacodynamics studies were also assessed in beta‐amyloid‐injected rats following quantification of Alzheimer's disease (AD) hallmarks like, Aβ(1–42), tau‐protein, glycogen synthase kinase‐3β levels, interleukin‐6 and tumor necrosis factor‐α for neuroinflammatory responses. Characterization studies revealed the conjugation on developed NLCs. The in vitro and in vivo results showed significant effects of SA decorated NLCs in reversing the damage by toxicant which was further characterized by the levels of neurotransmitters like acetylcholinesterase, butyrylcholinesterase. The results revealed significant (p < .05) refurbishment of cholinergic functions after 28 days of treatment of developed NLCs. These preclinical findings support the use of SA as a ligand to deliver the AA at targeted site as well as to mitigate the cognitive deficits in AD.

Journal of Liposome Research

Remote loading in liposome: a review of current strategies and recent developments

Review

作者: Dutta, Tathagata ; Gaur, Shreya ; Pandey, Ravi Shankar ; Nambiar, Navami Rajan ; Sudheesh, M S ; Ramachandran, Gayathri ; Nath, Lekshmi R ; M, Sabitha

Liposomes have gained prominence as nanocarriers in drug delivery, and the number of products in the market is increasing steadily, particularly in cancer therapeutics. Remote loading of drugs in liposomes is a significant step in the translation and commercialization of the first liposomal product. Low drug loading and drug leakage from liposomes is a translational hurdle that was effectively circumvented by the remote loading process. Remote loading or active loading could load nearly 100% of the drug, which was not possible with the passive loading procedure. A major drawback of conventional remote loading is that only a very small percentage of the drugs are amenable to this method. Therefore, methods for drug loading are still a problem for several drugs. The loading of multiple drugs in liposomes to improve the efficacy and safety of nanomedicine has gained prominence recently with the introduction of a marketed formulation (Vyxeos) that improves overall survival in acute myeloid leukemia. Different strategies for modifying the remote loading process to overcome the drawbacks of the conventional method are discussed here. The review aims to discuss the latest developments in remote loading technology and its implications in liposomal drug delivery.

项与 Jodas Expoim Pvt Ltd. 相关的新闻（医药）

2024-02-29

·PRNewswire

Asia-Pacific Contrast Media Agent and Injector System Markets, 2022-2024 and 2026: Nanoparticle Contrast Agents, Development of Safer Contrast Media Agents, Partnerships and Business are Key Trends

DUBLIN, Feb. 28, 2024 /PRNewswire/ -- The "Asia-Pacific Contrast Media Agent and Injector System Market - Analysis and Forecast, 2022-2026" report has been added to ResearchAndMarkets.com's offering. The Asia-Pacific contrast media agent and injector system market was valued at $1.98 billion in 2022 and is expected to reach $2.62 billion by 2026, growing at a CAGR of 7.24% during the forecast period 2022-2026 The market is driven due to factors like rising cases of cancer and cardiovascular diseases, which result in higher demand for contrast media agents, injector systems, and image-guided diagnostic procedures. The APAC Contrast Media Agent and Injector System Market is witnessing substantial growth driven by several key factors. Firstly, the rising incidence of medical conditions such as cancer and cardiovascular diseases has led to an increased demand for imaging procedures that require contrast media agents and injector systems. This is particularly crucial for accurate diagnosis and treatment planning. Secondly, advancements in medical imaging technologies have further fueled market growth. The development of innovative contrast media agents and injector systems has improved the precision and effectiveness of diagnostic procedures, making them more accessible and reliable for healthcare providers. Lastly, the expanding healthcare infrastructure and increasing healthcare expenditure in the Asia-Pacific region have contributed to the market's expansion. As healthcare facilities continue to modernize and upgrade their imaging capabilities, the demand for contrast media agents and injector systems is expected to continue its upward trajectory in the region. How can this report add value to an organization? Growth/Marketing Strategy: The APAC contrast media agent and injector system market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint ventures. Competitive Strategy: The APAC contrast media agent and injector system market consists of various leading manufacturers, small-medium enterprises, and emerging startups. With the increasing demand for advanced devices, companies can expand their presence in the market through different strategic approaches. Some of the strategies followed by the leading contributors are the launch of new products, mergers and acquisitions, and regulatory and legal approvals. Key Companies Profiled Beijing Beilu Pharmaceutical Co. Ltd. FUJIFILM Holdings Corporation Jiangsu Hengrui Pharmaceutical Co., Ltd. Jodas Expoim Pvt. Ltd. Shenzen Seacrown Electromechanical Co., Ltd. Sino Medical-Device Technology Co., Ltd. Unijules Life Sciences Ltd. Key Topics Covered: Executive Summary Scope of the Study Research Methodology 1 Markets 1.1 Market Outlook 1.1.1 Product Definition 1.1.2 Inclusion and Exclusion Criteria 1.2 Market Overview 1.3 Industry Outlook 1.3.1 Regulatory and Legal Requirements and Framework 1.3.1.1 Regulatory and Legal Requirements and Framework in Asia-Pacific 1.3.1.1.1 China 1.3.1.1.2 Japan 1.3.2 Patent Analysis 1.3.2.1 Patent Filing Trend (by Year) 1.3.2.2 Patent Filing Trend (by Country) 1.3.3 Key Trends 1.3.3.1 Nanoparticle-Based Contrast Agents 1.3.3.2 Development of Safer Contrast Media Agent 1.3.3.3 Partnerships and Business Alliances among Players for Strong Foothold in Different Regions 1.4 Impact of COVID-19 on Contrast Media Agent and Injector System Market 1.4.1 Pre-COVID-19 Impact 1.4.2 During COVID-19 Impact 1.4.3 Post-COVID-19 Impact 1.5 Market Dynamics 1.5.1 Impact Analysis 1.5.2 Market Drivers 1.5.2.1 Increasing Prevalence of Cancer and Cardiovascular Diseases Leading to Upsurge Demand of Imaging with Contrast Media Agents and Injector System 1.5.2.2 Upsurge in Demand for Image-Guided Diagnostics 1.5.2.3 Growing Number of Regulatory Approvals 1.5.3 Market Restraints 1.5.3.1 Rising Health Concerns Post Usage of Contrast Media Agents in Body 1.5.4 Market Opportunities 1.5.4.1 IT Advances in Contrast Media Injectors 2 Region 2.1 Overview 2.2 Asia-Pacific 2.2.1 Key Findings 2.2.2 Market Dynamics 2.2.2.1 Impact Analysis 2.2.3 Market Size and Forecast 2.2.3.1 Asia-Pacific Contrast Media Agent and Injector System Market (by Product) 2.2.3.1.1 Asia-Pacific Contrast Media Injector System Market (by Product) 2.2.3.2 Asia-Pacific Contrast Media Agent and Injector System Market (by Country) 2.2.3.2.1 China 2.2.3.2.2 Japan 2.2.3.2.3 India 2.2.3.2.4 Australia 2.2.3.2.5 Rest-of-Asia-Pacific 3 Markets - Competitive Benchmarking & Company Profiles 3.1 Competitive Benchmarking 3.1.1 Key Strategies and Development 3.1.1.1 Regulatory and Legal Activities 3.1.1.2 Partnerships, Collaborations, and Business Expansions 3.1.1.3 Mergers and Acquisitions 3.1.1.4 New Offerings 3.1.2 Market Share Analysis 3.1.2.1 Market Share Analysis, by Contrast Media Agent Market 3.1.2.2 Market Share Analysis, by Contrast Media Injector System Market 3.2 Contrast Media Ecosystem Active Players 3.3 Company Profiles 3.3.1 Company Overview 3.3.2 Role of Beijing Beilu Pharmaceutical Co. Ltd. in the Contrast Media Agent and Injector System Market 3.3.3 Recent Developments 3.3.4 Analyst Perception For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 项与 Jodas Expoim Pvt Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Jodas Expoim Pvt Ltd. 相关的转化医学

登录后查看更多信息